Artiva Historical Income Statement
| ARTV Stock | 11.04 0.64 6.15% |
Historical analysis of Artiva Biotherapeutics, income statement accounts such as Interest Income of 2.7 M, Depreciation And Amortization of 2.4 M or Interest Expense of 0.0 can show how well Artiva Biotherapeutics, Common performed in making a profits. Evaluating Artiva Biotherapeutics, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Artiva Biotherapeutics,'s future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Artiva Biotherapeutics, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Artiva Biotherapeutics, is a good buy for the upcoming year.
Artiva |
About Artiva Income Statement Analysis
Artiva Biotherapeutics, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Artiva Biotherapeutics, shareholders. The income statement also shows Artiva investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Artiva Biotherapeutics, Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Artiva Biotherapeutics,. It is also known as Artiva Biotherapeutics, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Artiva Biotherapeutics, operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Artiva Biotherapeutics, Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Artiva Biotherapeutics, Common minus its cost of goods sold. It is profit before Artiva Biotherapeutics, operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Artiva Biotherapeutics,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Artiva Biotherapeutics, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artiva Biotherapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Artiva Biotherapeutics,'s Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 2.7 M in 2024, whereas Operating Income is likely to drop (32.2 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 248K | 1.2M | 2.3M | 2.4M | Total Operating Expenses | 55.3M | 64.8M | 64.2M | 55.7M |
Artiva Biotherapeutics, income statement Correlations
Click cells to compare fundamentals
Artiva Biotherapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.